Read More

Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday – Read Here Why

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.

AEON

Read More

Johnson & Johnson Announces Phase 2 Data For ERLEADA Plus Androgen Deprivation Therapy Following Radical Prostatectomy In Patients With High-Risk Localized Prostate Cancer Show 100% Biochemical Free Recurrence Rate More Than Two Years Post-Surgery; Stu…

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of

JNJ

Read More

CG Oncology Announces Data From The Phase 3 BOND-003 Study Evaluating The Efficacy And Safety Of Cretostimogene Monotherapy, Demonstrated 75.2% Complete Response Rate In High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT

CGON

Read More

Kodiak Sciences Data At ARVO 2024 Highlight Depth Of Early And Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built On Kodiak’s Antibody Biopolymer Conjugate Platform

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple

KOD

Read More

enGene To Present Details Of Its Pivotal Phase 1/2 LEGEND Study Of EG-70 In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ At The American Urology Association 2024 Annual Meeting

Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerationsBOSTON and MONTREAL, May 2, 2024 /CNW/

ENGN